Equities

Zenith Drugs Ltd

ZENITHDRUG:NSI

Zenith Drugs Ltd

Actions
  • Price (INR)126.40
  • Today's Change-7.35 / -5.50%
  • Shares traded153.60k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Income statement Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 202320232022
REVENUE AND GROSS PROFIT
Total revenue1,145917
OPERATING EXPENSES
Cost of revenue total852726
Selling, general and admin. expenses, total4737
Depreciation/amortization1313
Unusual expense(income)----
Other operating expenses, total14985
Total operating expense1,062862
Operating income8455
Other, net8.127.19
INCOME TAXES, MINORITY INTEREST AND EXTRA ITEMS
Net income before taxes7244
Provision for income taxes2113
Net income after taxes5231
Minority interest0.00(0.1)
Net income before extra. Items5231
Total extraordinary items----
Net income5231
Inc.avail. to common excl. extra. Items5231
Inc.avail. to common incl. extra. Items5231
EPS RECONCILIATION
Basic/primary weighted average shares1717
Basic/primary eps excl. extra items3.001.82
Basic/primary eps incl. extra items3.001.82
Dilution adjustment----
Diluted weighted average shares1717
Diluted eps excl. extra items3.001.82
Diluted eps incl. extra items3.001.82
COMMON STOCK DIVIDENDS
DPS - common stock primary issue----
Gross dividend - common stock----
PRO FORMA INCOME
Pro forma net income----
Interest expense, supplemental2018
SUPPLEMENTAL INCOME
Depreciation, supplemental1313
Total special items----
NORMALISED INCOME
Normalized income before taxes7244
Effect of special items on income taxes----
Income tax excluding impact of special items2113
Normalized income after tax5231
Normalized income avail. to common5231
Basic normalized EPS3.001.82
Diluted normalized EPS3.001.82
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.